Skip to content
Companies

SonoThera

Ultrasound-delivered gene therapies without viral vectors

Raised to date

$125.5M

of $125.5M offered across 1 Form D filing

Investors
22
Last filed
Jun 30, 2026

About

SonoThera develops nonviral genetic medicines delivered with focused clinical ultrasound. Its RIPPLE platform pairs proprietary acoustic profiles with circulating gas-filled microbubbles to transiently open cell membranes and deliver genetic payloads into targeted organs without a viral vector. Lead preclinical programs target Duchenne muscular dystrophy, autosomal dominant polycystic kidney disease, X-linked Alport syndrome, hemophilia A, and cardiac indications, with first clinical trials planned for 2027. The company raised a $60.75M Series A and closed an oversubscribed $125M Series B.

Because delivery is physical rather than viral, the platform is redosable, carries payloads of effectively unlimited size (DNA, RNA, gene editors, siRNA, ASOs), and avoids the immunogenicity and dosing ceilings that constrain AAV and lipid-nanoparticle approaches, while targeting nearly any organ using standard clinical ultrasound equipment.

Funding

  • EquityFiled Jun 30, 2026Form D
    $125.5M/ $125.5M

Product

RIPPLE

Genetic medicine delivery platform

An ultrasound-mediated delivery (UMD) platform that combines proprietary acoustic profiles with microbubbles to transiently open pathways into cells in a targeted organ, allowing genetic payloads to enter without a viral vector.

  • Nonviral, ultrasound-guided delivery using standard clinical ultrasound
  • Broad but highly targeted biodistribution with limited off-target exposure
  • Payloads of unlimited size: DNA, RNA, gene editors, siRNAs, ASOs

Built for

Patients with serious monogenic and organ-specific genetic diseases, reached through clinicians, health systems, and biopharma partners

People on file